Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

CGRP Antibodies as Prophylaxis in Migraine

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Drug-Driven Phenotypic Convergence Supports Rational Treatment Strategies of Chronic Infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

  1. Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Does inflammation have a role in migraine?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. The changing faces of migraine

    Publikation: Bidrag til tidsskriftLederForskningpeer review

Vis graf over relationer

Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (CLR + RAMP1) offer considerable improvements over existing drugs in migraine prophylaxis and are the first designed to act on the trigeminal pain system. Erenumab is approved by the FDA and EMA and has reached the market since May 2018. Two antibodies, fremanezumab and galcanezumab, directed towards the CGRP ligand, were approved by the FDA in September 2018. To view this Bench to Bedside, open or download the PDF.

OriginalsprogEngelsk
TidsskriftCell
Vol/bind175
Udgave nummer7
Sider (fra-til)1719
ISSN0092-8674
DOI
StatusUdgivet - 2018
Eksternt udgivetJa

ID: 55839281